Clinical Trial Update: Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) [Phase 3]

View source ↗

Summary

Phase 3 trial PREFER-HF evaluating intravenous iron therapy in patients with heart failure with preserved ejection fraction and iron deficiency anemia has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Institut de Recerca Biomèdica de Lleida | Conditions: Heart Failure With Normal Ejection Fraction, Ferropenic Anemia | Phase 3 | Status: COMPLETED